Healthcare, Pharma & Life Sciences

Nanomedicine Market to Nearly Triple to $581.2B by 2034

Image
Nanomedicine Market to Nearly Triple to $581.2B by 2034

Pune, India – September 25, 2026 -- The global nanomedicine market reached USD 207.91 billion in 2025 and is projected to hit USD 581.2 billion by 2034, expanding at a 12.1% compound annual growth rate, according to a new report from Maximize Market Research.

North America commands the largest share on pharmaceutical R&D strength

North America held the largest share of the market in 2025, driven by advanced healthcare infrastructure, deep pharmaceutical and biotechnology research pipelines, and high healthcare expenditure. The United States anchors regional growth through its established research ecosystem and rising adoption of nanotechnology-based drug delivery, diagnostics and precision medicine platforms. Canada and Mexico are contributing through expanding healthcare capabilities and research initiatives.

MS Treatment Market to Hit $44.45B by 2034 on DMT Demand

Image
MS Treatment Market to Hit $44.45B by 2034 on DMT Demand

Pune, India – September 25, 2026 -- The global multiple sclerosis treatment market reached USD 26.76 billion in 2025 and is forecast to climb to USD 44.45 billion by 2034, expanding at a 5.8% CAGR, according to a new report from Maximize Market Research.

Disease-modifying therapies and biologics drive current market expansion

Rising MS prevalence, improved diagnostic capabilities, and growing adoption of immunomodulators, immunosuppressants, interferons, oral disease-modifying therapies (DMTs), and monoclonal antibodies are fueling demand across relapsing-remitting (RRMS), primary progressive (PPMS), secondary progressive (SPMS), and clinically isolated syndrome (CIS) patient segments. High-efficacy biologics and oral treatment options are increasingly displacing older therapy classes as patients and physicians prioritize convenience and disease-progression control.

Placenta Market to Hit $275 Billion by 2034 on Cosmetics Boom

Image
Placenta Market to Hit $275 Billion by 2034 on Cosmetics Boom

Pune, India – September 25, 2026 -- The global placenta market is set to nearly triple from USD 96.1 billion in 2025 to USD 275.18 billion by 2034, expanding at a 12.4% compound annual growth rate, according to a new analysis by Maximize Market Research.

Asia-Pacific leads global demand as Japan, South Korea and China drive placenta research

Asia-Pacific held the leading market position in 2025, backed by strong placenta research and development in Japan, South Korea and China, alongside rising production of placenta-derived products for pharmaceutical and cosmetics applications. The region's large consumer base and appetite for anti-aging and skincare solutions continue to underpin its dominant position.

Bioinformatics Market to Hit $64.60B by 2034 on NGS, AI Demand

Image
Bioinformatics Market to Hit $64.60B by 2034 on NGS, AI Demand

Pune – September 25, 2026 -- The global bioinformatics market is projected to expand from $20.34 billion in 2025 to $64.60 billion by 2034, a 13.7% compound annual growth rate, according to new analysis from Maximize Market Research.

Genomic data volumes and NGS adoption fuel core demand

Rising volumes of genomic and biological data, driven by expanding next-generation sequencing (NGS) adoption, are pushing pharmaceutical and biotechnology companies toward advanced bioinformatics platforms, sequencing data analysis tools, and biological databases. Declining sequencing costs are drawing smaller research institutions into the market, while growing precision medicine applications are increasing demand for pharmacogenomics, biomarker analysis, and genomic diagnostics.

Study: 55% of AD Patients Switch Systemic Therapy Over Efficacy Gaps

Image
Study: 55% of AD Patients Switch Systemic Therapy Over Efficacy Gaps

Friendswood, Texas – September 25, 2026 -- More than half of atopic dermatitis (AD) patients who used targeted systemic therapies modified treatment because the drugs failed to work, according to a new study published in Dermatology and Therapy by Castle Biosciences, Inc. (Nasdaq: CSTL).

Study finds 55% of systemic therapy users switched due to lack of efficacy

The research surveyed 43 AD patients and caregivers who completed a 32-question assessment at the 2024 National Eczema Association Eczema Expo. Among respondents who had used targeted systemic therapies, 55% reported modifying treatment because of insufficient results. Inadequate skin clearance and persistent itching were cited as the most frequent reasons for switching drugs or adding topical treatments.

NORD Honors Six Firms for First-of-Kind Rare Disease Therapy Approvals

Image
NORD Honors Six Firms for First-of-Kind Rare Disease Therapy Approvals

Norwell, Mass. – September 25, 2026 -- The National Organization for Rare Disorders (NORD) has named six companies and nonprofits as 2026 Industry Innovator honorees for delivering first-of-their-kind FDA-approved therapies to patients with rare diseases that affect a fraction of the more than 30 million Americans living with such conditions.

Six FDA approvals mark milestones across ultra-rare indications

Mighty Therapeutics was recognized for FORZINITY, the first therapy for Barth syndrome, a rare mitochondrial disease, shown to improve muscle strength and quality of life. UCB earned recognition for KYGEVVI, the first and only approved treatment for thymidine kinase 2 deficiency in patients whose symptoms began at or before age 12. Fondazione Telethon was honored for Waskyra, a gene therapy for Wiskott-Aldrich syndrome that stands as the first FDA-approved gene therapy for a primary immunodeficiency disorder and the first developed by a nonprofit.

RFU Neuroscientist Wins $2.3M NIH Grant to Study Teen Brain Isolation Effects

Image
RFU Neuroscientist Wins $2.3M NIH Grant to Study Teen Brain Isolation Effects

North Chicago, Illinois – September 25, 2026 -- Rosalind Franklin University of Medicine and Science (RFU) neuroscientist Nicole Ferrara, PhD, has secured a five-year, $2.3 million grant from the National Institutes of Health to investigate how social disruptions, including COVID-19 lockdowns, alter brain development in adolescents.

NIH funds five-year study on amygdala development and social behavior

The project, titled "Social Experience Guides BMA Mediated Social Development," will examine how the basomedial amygdala (BMA) responds to restricted or inconsistent social contact during adolescence and young adulthood. Dr. Ferrara's preliminary data indicate the BMA functions differently during teen and young adult years compared with other brain regions, making it potentially more vulnerable to social disruption.

NYU Langone Recruits Three Top Orthopedic Surgeons to Expand Sports Medicine

Image
NYU Langone Recruits Three Top Orthopedic Surgeons to Expand Sports Medicine

New York City – September 25, 2026 -- NYU Langone Health has recruited three senior orthopedic surgeons -- Dr. Sabrina M. Strickland, Dr. F. Winston Gwathmey, and Dr. Andreas H. Gomoll -- to lead new specialty centers within its orthopedics division, currently ranked No. 2 nationally by U.S. News & World Report.

NYU Langone builds out joint-preservation leadership with three senior hires

Dr. Strickland arrives from the Hospital for Special Surgery in Manhattan, where she practiced for more than two decades, to become the inaugural director of NYU Langone's new Center for Patellofemoral Disorders. Her clinical focus spans knee cartilage repair, patellar stabilization, ACL and meniscus surgery, and joint preservation; she also uses 3D-printed joint models to refine surgical techniques for patients with atypical bone structures, addressing a gap left by biomechanical research that relies primarily on cadaveric 'normal' joints.

The Inner Circle Names Dr. Lee Drinkard Pinnacle Lifetime Member

Image
The Inner Circle Names Dr. Lee Drinkard Pinnacle Lifetime Member

Irving, Texas – – September 25, 2026 -- The Inner Circle has named Dr. Lee Campbell Drinkard, MD, FACP, a Pinnacle Lifetime Member for his career in hematology, oncology and palliative care.

Drinkard practices locum tenens across multiple states, treating malignant and benign tumors

Dr. Drinkard currently works as a locum tenens physician, traveling nationwide to consult on complex hematology and oncology cases, including both malignant and benign tumors. His practice also extends to hospice and palliative care for patients managing life-limiting illness.

Drinkard holds four board certifications spanning internal medicine to palliative care

He is board certified in internal medicine, hematology, oncology, and hospice and palliative care. Drinkard is also a Fellow of the American College of Physicians, the credential reflected in his FACP designation.

MyOme Launches Global Genomic Risk Platform on Oracle Cloud

Image
MyOme Launches Global Genomic Risk Platform on Oracle Cloud

Menlo Park, Calif. – September 25, 2026 -- MyOme, Inc. has made its predictive genomic insights platform and testing services available worldwide by running them on Oracle Cloud Infrastructure (OCI), the companies announced.

MyOme joins Oracle PartnerNetwork to widen healthcare distribution

The clinical whole-genome analysis firm has also joined Oracle PartnerNetwork (OPN), enabling distribution of its capabilities through the Oracle ecosystem and Oracle Marketplace to a broader base of healthcare organizations.